Close Menu

University College London

The company has been authorized by the state of New Jersey to provide sequencing-based cancer detection and surveillance using patient-specific ctDNA assays.

In Science this week: machine learning model predicts whether ion channel mutations will cause disease, and more.

In Cell this week: blood immune cell changes in COVID-19 patients and spatial transcriptomics in Alzheimer's disease.

An analysis of societal and health system cost-effectiveness and outcomes points to the benefits of expanding pathogenic BRCA1/2 variant testing in six countries.

Next Steps to Take

New Scientist describes next steps supporters of the #ShutdownSTEM strike could take to combat racism in academia.

ArcherDx will develop sequencing-based circulating tumor DNA assays for use in AstraZeneca's recently launched Phase III MERMAID-1 trial of durvalumab (Imfinzi).

Researchers argued that the field is ready for an expansion of adjuvant therapy trials informed by non-invasive, molecular measures of minimal residual disease.

Using data for more than half a million individuals, researchers identified 449 refractive area-related loci, including 336 sites not linked to the eye condition in the past.

Resignation Call

The Observer reports that there have been calls for a University of College London geneticists to resign due to research fraud coming out of his lab.

A genome-wide association meta-analysis involving almost one million heart failure cases and controls identified 11 risk loci and helped distinguish potential causal contributors.

Pages

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.